Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024

被引：2

作者：

De Mattia, G. ^{[1
]}

Maffi, M. ^{[1
]}

Mazzantini, M. ^{[1
]}

机构：

[1] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Pisa, Italy

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2024年 / 42卷 / 07期

关键词：

osteoporosis; fragility fracture; abaloparatide; trabecular bone score; sequential therapy; TRABECULAR BONE SCORE; POSTMENOPAUSAL WOMEN; ABALOPARATIDE; TERIPARATIDE; ALENDRONATE; PREVENTION; MANAGEMENT; DENOSUMAB; THERAPY; TBS;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis is a skeletal disease charunderlying a higher risk of fragility fractures. Several options are available for its treatment, including both anti-resorptive and anabolic agents. The present review discusses and summarises the most recent literature on anabolic treatment, with a focus on abaloparatide, and on the assessment of fragility fracture risk, with a focus on trabecular bone score. Finally, we provide a discussion on the effects of different antiosteoporotic medications in terms of fragility fracture risk reduction.

引用

页码：1311 / 1316

页数：6

共 37 条

[1] Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis A Living Systematic Review and Network Meta-analysis for the American College of Physicians [J].

Ayers, Chelsea ;

Kansagara, Devan ;

Lazur, Brittany ;

Fu, Rongwei ;

Kwon, Amy ;

Harrod, Curtis .

ANNALS OF INTERNAL MEDICINE, 2023, 176 (02) :182-195

[2] ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis [J].

Bone, Henry G. ;

Cosman, Felicia ;

Miller, Paul D. ;

Williams, Gregory C. ;

Hattersley, Gary ;

Hu, Ming-yi ;

Fitzpatrick, Lorraine A. ;

Mitlak, Bruce ;

Papapoulos, Socrates ;

Rizzoli, Rene ;

Dore, Robin K. ;

Bilezikian, John P. ;

Saag, Kenneth G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08) :2949-2957

[3]

Carey JJ, 2018, CLIN EXP RHEUMATOL, V36, pS115

[4] The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence [J].

Chandran, Manju .

ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (05) :724-738

[5] Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend [J].

Cosman, Felicia ;

Hans, Didier ;

Shevroja, Enisa ;

Wang, Yamei ;

Mitlak, Bruce .

JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 (04) :464-470

[6] Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose? [J].

Cosman, Felicia ;

Dempster, David W. .

CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (02) :189-205

[7] Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe [J].

Davenport, Colleen ;

Gravel, Patricia ;

Wang, Yamei ;

Williams, Setareh A. ;

Wieland, Alethea ;

Mitlak, Bruce .

THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (03) :505-518

[8] Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis [J].

Dempster, David W. ;

Zhou, Hua ;

Rao, Sudhaker D. ;

Recknor, Chris ;

Miller, Paul D. ;

Leder, Benjamin Z. ;

Annett, Miriam ;

Ominsky, Michael S. ;

Mitlak, Bruce H. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (04) :644-653

[9] Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study [J].

Dhaliwal, Ruban ;

Hans, Didier ;

Hattersley, Gary ;

Mitlak, Bruce ;

Fitzpatrick, Lorraine A. ;

Wang, Yamei ;

Schwartz, Ann V. ;

Miller, Paul D. ;

Josse, Robert G. .

JBMR PLUS, 2020, 4 (04)

[10] Patient treatment preferences for osteoporosis [J].

Fraenkel, Liana ;

Gulanski, Barbara ;

Wittink, Dick .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (05) :729-735

← 1 2 3 4 →